CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER Drug Patent Profile

When do Cefepime And Dextrose In Duplex Container patents expire, and what generic alternatives are available?

Cefepime And Dextrose In Duplex Container is a drug marketed by B Braun and is included in one NDA.

The generic ingredient in CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER is cefepime hydrochloride. There is one drug master file entry for this compound. Ten suppliers are listed for this compound. Additional details are available on the cefepime hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cefepime And Dextrose In Duplex Container

A generic version of CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER was approved as cefepime hydrochloride by ACS DOBFAR on March 20^th, 2008.

Summary for CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	1,390
DailyMed Link:	CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER at DailyMed

Pharmacology for CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

Drug Class

Cephalosporin Antibacterial

US Patents and Regulatory Information for CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun	CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER	cefepime hydrochloride	INJECTABLE;INJECTION	050821-001	May 6, 2010		RX	Yes	Yes
B Braun	CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER	cefepime hydrochloride	INJECTABLE;INJECTION	050821-002	May 6, 2010		RX	Yes	Yes

Cefepime and Dextrose in DUPLEX Container: Market Dynamics, Patent Position, and Financial Trajectory

Last updated: September 24, 2026

Cefepime and Dextrose Injection in the DUPLEX container is a mature, generic hospital antibiotic marketed primarily for institutional use. Its commercial value comes from premixed, ready-to-administer packaging rather than molecule-level exclusivity. The product has no meaningful biosimilar exposure, limited patent protection around cefepime itself, and a market shaped by hospital contracting, injectable-drug shortages, manufacturing capacity, and price competition.

Public filings do not separately report product-level revenue for Cefepime and Dextrose in DUPLEX containers. The likely financial trajectory is mature and volume-driven, with revenue sensitive to hospital demand, supply continuity, contract wins, and the premium hospitals place on ready-to-use containers.

What is Cefepime and Dextrose in the DUPLEX container?

Cefepime and Dextrose Injection is a premixed intravenous product containing cefepime hydrochloride, an injectable fourth-generation cephalosporin, in a dextrose solution. The DUPLEX container is a dual-chamber flexible container that separates the drug powder from the diluent until activation.

The product is used for hospital treatment of susceptible bacterial infections, including pneumonia, febrile neutropenia, urinary tract infections, skin and skin-structure infections, and intra-abdominal infections when used with metronidazole. Its FDA labeling includes adult and pediatric dosing information and warnings concerning serious hypersensitivity, neurotoxicity, and Clostridioides difficile-associated diarrhea. [1]

Typical presentations include:

Product characteristic	Commercial description
Active ingredient	Cefepime hydrochloride
Diluent	Dextrose injection
Route	Intravenous infusion
Container	DUPLEX dual-chamber container
Common strengths	1 g and 2 g cefepime presentations, subject to product-specific labeling
Primary customers	Hospitals, integrated delivery networks, group purchasing organizations, and specialty distributors
Product type	Generic premixed injectable antibiotic
Regulatory category	Abbreviated New Drug Application product
Primary commercial differentiator	Ready-to-use preparation and reduced pharmacy compounding

The DUPLEX design reduces preparation steps compared with conventional cefepime vials that require reconstitution and dilution. That benefit can reduce pharmacy labor and preparation errors, although it generally carries a higher acquisition cost than bulk vial presentations.

Who manufactures Cefepime and Dextrose in the DUPLEX container?

B. Braun Medical Inc. is associated with the Cefepime and Dextrose Injection product in the DUPLEX container. B. Braun’s U.S. portfolio includes intravenous solutions, infusion devices, premixed medications, and hospital pharmacy products.

The product competes with conventional cefepime injection vials supplied by multiple generic manufacturers. Competition therefore occurs at two levels:

1. Cefepime molecule competition from vial manufacturers.
2. Ready-to-administer premix competition from manufacturers with compatible container and manufacturing capabilities.

The relevant competitive set can include:

• Cefepime for Injection supplied in single-dose vials.
• Cefepime premixed in standard IV bags.
• Other hospital-administered beta-lactam antibiotics.
• Alternative broad-spectrum agents selected under institutional antimicrobial stewardship policies.

The DUPLEX product is not competing only on active ingredient price. Its value proposition includes inventory simplification, reduced compounding workload, and predictable administration workflow.

What is the FDA regulatory status of Cefepime and Dextrose in DUPLEX?

The product is an FDA-approved generic injectable drug. Its labeling identifies cefepime hydrochloride as the active pharmaceutical ingredient and dextrose as the diluent in a dual-chamber container. [1]

The principal regulatory requirements are:

Regulatory issue	Impact on the product
ANDA approval	Requires pharmaceutical equivalence and bioequivalence or other applicable approval evidence
Sterile manufacturing	Creates higher compliance and quality-control requirements than oral generics
Container-closure integrity	Critical to maintaining sterility and product stability
Reconstitution instructions	Must be followed to activate the drug and diluent chambers
Stability and storage	Limits manufacturing, inventory, and distribution flexibility
Labeling	Must address renal dose adjustment, hypersensitivity, neurotoxicity, and administration requirements

Cefepime requires dose adjustment in patients with renal impairment. The FDA label warns that unadjusted dosing can increase the risk of encephalopathy, myoclonus, seizures, and nonconvulsive status epilepticus. [1] These clinical considerations affect hospital formulary placement and stewardship controls.

What patents protect Cefepime and Dextrose in the DUPLEX container?

The active pharmaceutical ingredient is a mature, off-patent small molecule. The original composition and product exclusivity associated with cefepime have expired, allowing broad generic competition.

The commercial protection for the DUPLEX presentation is more likely to depend on:

• Container architecture.
• Manufacturing processes.
• Drug-diluent separation and activation systems.
• Sterile filling and packaging know-how.
• Product-specific stability data.
• Trade secrets and quality systems.

These rights are different from patents listed in the FDA Orange Book for an approved drug product. The Orange Book primarily identifies patents and exclusivity associated with FDA-approved reference listed drugs and qualifying products. A generic premixed product does not ordinarily obtain a durable molecule patent position merely because it uses a proprietary container. [2]

Is Cefepime and Dextrose in DUPLEX listed in the Orange Book?

The product’s commercial position is not based on a material Orange Book patent estate. Cefepime is widely available as a generic active ingredient, and the relevant competitive barriers are manufacturing and supply-chain barriers rather than statutory exclusivity.

A container patent, if applicable, may be enforceable independently of the Orange Book. Such a patent would need to be analyzed by claims, expiration, ownership, prosecution history, and infringement risk. It would not automatically block all cefepime generic products.

When does Cefepime and Dextrose in DUPLEX lose exclusivity?

The molecule-level exclusivity period has already expired. There is no evident commercial exclusivity comparable to a new chemical entity, orphan drug, pediatric extension, or innovative biologic exclusivity.

Exclusivity category	Position
New chemical entity exclusivity	Expired or not applicable to the current generic product
Orphan drug exclusivity	Not applicable
Biologic exclusivity	Not applicable
Pediatric exclusivity	No material current barrier identified
Formulation exclusivity	No publicly established long-term exclusivity identified
Container-related exclusivity	Potentially relevant only if a valid, unexpired patent applies
Generic competition	Established

Any patent analysis must separate patents covering cefepime from patents covering a specific ready-to-use container. A container patent would not necessarily prevent a competitor from selling cefepime in a conventional vial, another IV bag, or a different dual-chamber system.

Are there Paragraph IV challenges to Cefepime and Dextrose in DUPLEX?

A Paragraph IV certification is relevant when an ANDA applicant challenges a patent listed for the reference drug in the Orange Book. [3] The commercial significance of Paragraph IV litigation is low for a mature cefepime premix unless a currently listed, enforceable patent covers the specific product or an associated formulation.

The likely regulatory risk profile is:

Challenge type	Relevance
Paragraph IV against cefepime molecule patent	Low, because core molecule exclusivity has expired
Paragraph IV against a premixed formulation patent	Possible in principle, but dependent on a listed patent
Paragraph IV against container technology	Usually analyzed outside the central Orange Book pathway
Section viii method-of-use carve-out	Possible if a protected indication exists, though cefepime’s primary indications are mature
ANDA approval risk	More likely tied to manufacturing, sterility, labeling, or bioequivalence than patent disputes

No major public Paragraph IV litigation is associated with the mature cefepime molecule comparable to litigation involving newer branded drugs.

What formulation patents protect the DUPLEX presentation?

The strongest potential IP around the product is presentation-specific rather than molecule-specific. Relevant claim categories could include:

• Dual-compartment containers for unstable injectable combinations.
• Breakable seals or activation mechanisms.
• Cefepime powder stability in the drug chamber.
• Dextrose compatibility and concentration.
• Container materials that limit adsorption or leachables.
• Sterile manufacturing and filling processes.
• Storage conditions and reconstitution performance.

The commercial value of these rights depends on claim scope. A narrow claim covering one container geometry may not prevent a competitor from designing around it. A broader claim covering the drug-diluent separation system or activation method could create a stronger barrier, but its practical value would still depend on enforceability and remaining patent term.

Trade secrets may be more important than patents for manufacturing yield, aseptic processing, packaging reliability, and shelf-life performance.

How strong is the patent estate for Cefepime and Dextrose in DUPLEX?

The patent estate is weak at the molecule level and potentially moderate at the product-presentation level.

IP layer	Strength	Commercial effect
Cefepime active ingredient	Low	Broad generic access
Cefepime therapeutic use	Low to moderate	Limited protection for mature hospital indications
Premixed formulation	Moderate if claims are valid and unexpired	May delay direct premix competition
DUPLEX container	Moderate, depending on claim scope	May protect manufacturing or presentation design
Manufacturing know-how	Potentially strong	Difficult to replicate quickly, but not statutory exclusivity
Trademarks and branding	Low to moderate	Supports product identification but does not block generic cefepime

The main competitive moat is operational. Sterile injectable manufacturing requires validated facilities, regulatory compliance, reliable component supply, and a record of acceptable quality performance.

What market dynamics affect sales of the DUPLEX product?

Hospital antibiotic demand is relatively resilient because cefepime is used for serious infections. Volume does not track retail prescription trends. Key demand drivers include:

• Hospital admissions and intensive-care utilization.
• Gram-negative infection prevalence.
• Febrile neutropenia treatment protocols.
• Antimicrobial-resistance patterns.
• Hospital stewardship policies.
• Availability of competing beta-lactams.
• Injectable-drug shortages.
• Group purchasing organization contracts.

Cefepime is often held as a broad-spectrum hospital antibiotic, but stewardship programs can restrict its use or require infectious-disease approval. That creates a ceiling on volume even when the product is clinically important.

The premixed format can gain share when hospitals face pharmacy labor shortages or seek to reduce sterile compounding. It can lose share when procurement departments prioritize the lowest unit acquisition cost and use vial-based cefepime.

What is the financial trajectory for Cefepime and Dextrose in DUPLEX?

The product is best characterized as a mature generic with stable-to-declining price economics and episodic volume upside.

Financial driver	Expected effect
Molecule maturity	Sustained price pressure
Ready-to-use format	Supports price premium over vials
Hospital labor costs	Favors premixed products
GPO contracting	Compresses net price
Sterile manufacturing scarcity	Can support pricing during shortages
Competitor entry	Reduces price and contract leverage
Cefepime demand	Supports recurring institutional volume
Product discontinuation or shortage	Can create temporary revenue volatility
B. Braun portfolio integration	May improve cross-selling through infusion accounts

The product’s revenue is unlikely to be material to B. Braun’s consolidated financial results by itself. It may be strategically valuable as part of a broader hospital portfolio that combines infusion solutions, administration devices, premixed drugs, and pharmacy products.

A likely financial pattern is:

1. Stable baseline demand from hospital formularies.
2. Price erosion as vial and premix competitors expand.
3. Temporary revenue increases during cefepime or injectable-antibiotic shortages.
4. Margin pressure from labor, quality, packaging, and sterile-manufacturing costs.
5. Greater value from contract retention than from premium pricing.

Public company disclosures generally aggregate hospital pharmaceutical and infusion revenue rather than reporting sales for this individual SKU. Product-level revenue, gross margin, and customer concentration are therefore not publicly established.

Which companies are challenging the product commercially?

The competitive threat comes less from a single branded challenger than from multiple supply models:

• Generic manufacturers selling cefepime vials.
• Premix suppliers offering cefepime in conventional IV bags.
• Hospital pharmacy compounding operations.
• Other broad-spectrum antibiotics used under institutional protocols.
• Contract manufacturers with sterile injectable capacity.

A competitor does not need to reproduce the DUPLEX container to pressure pricing. A lower-cost vial can substitute for the product where pharmacy capacity is available. Conversely, during staffing shortages or injectable supply disruptions, the DUPLEX format can command greater purchasing interest.

What generic launch scenarios exist?

Three scenarios define the commercial outlook.

Base case: mature institutional product

Hospitals continue to use cefepime, while procurement teams negotiate lower prices. The DUPLEX container maintains a niche based on preparation efficiency and workflow reliability.

Upside case: supply disruption or pharmacy labor pressure

Shortages of cefepime vials, competing beta-lactams, or sterile compounding capacity increase demand for ready-to-use products. B. Braun benefits if it has available manufacturing capacity and stable component supply.

Downside case: direct premix competition

A competitor launches a comparable premixed cefepime product, leading to contract displacement, lower net pricing, and reduced value for the DUPLEX presentation. A broad shift toward alternative antibiotics would create a second source of volume erosion.

Does Cefepime and Dextrose have biosimilar risk?

No. Cefepime is a small-molecule antibiotic, not a biologic. Biosimilar substitution rules do not apply. Competitive entry occurs through the generic drug pathway, including ANDA approval, rather than through the 351(k) biosimilar pathway. [3]

What licensing deals affect the product?

No major publicly disclosed licensing transaction is central to the commercial identity of Cefepime and Dextrose in the DUPLEX container. Its economics are more likely governed by manufacturing, distribution, hospital contracting, and component-supply arrangements than by a high-value branded licensing deal.

What geographic markets are relevant?

The primary commercial market is the United States hospital sector. The product’s container technology and regulatory approvals may have relevance in other jurisdictions, but market access depends on country-specific sterile-drug approvals, procurement systems, reimbursement, and local competitors.

The United States has particularly strong demand for ready-to-administer injectable products because of hospital pharmacy workload, shortage management, and centralized purchasing. Europe and other markets may favor different premix formats, local suppliers, or hospital compounding models.

Key Takeaways

• Cefepime and Dextrose in the DUPLEX container is a mature generic hospital injectable.
• Its value comes from ready-to-use packaging, not active-ingredient exclusivity.
• Cefepime molecule patents do not create a meaningful current barrier to generic competition.
• Any material IP advantage would likely relate to the DUPLEX container, formulation stability, or manufacturing process.
• Paragraph IV and biosimilar risks are limited relative to newer branded or biologic products.
• Revenue is not publicly reported at the individual product level.
• The financial trajectory is likely stable but price-sensitive, with upside during injectable-drug shortages and downside from premix or vial competition.
• Manufacturing capacity, sterility compliance, supply continuity, and hospital contracts are more important than patent duration.
• The product can retain commercial relevance even without strong exclusivity because hospitals value reduced preparation burden and operational reliability.

FAQs

Is Cefepime and Dextrose in DUPLEX a branded drug or a generic?

It is a generic cefepime injectable product marketed in a proprietary dual-chamber container format.

Can a hospital substitute cefepime vials for the DUPLEX container?

Yes, subject to institutional pharmacy procedures, prescribing requirements, dose preparation, and product availability. Vials are generally a lower-cost substitute but require reconstitution and dilution.

Does the DUPLEX container create a patent monopoly over cefepime?

No. Container-related rights, if valid and enforceable, would generally cover particular packaging or manufacturing features rather than the cefepime molecule itself.

Why might hospitals pay more for a premixed cefepime product?

Hospitals may accept a price premium when the product reduces pharmacy labor, preparation steps, compounding risk, inventory complexity, or time to administration.

What is the main investment risk for this product?

The main risks are price erosion, direct premix competition, vial substitution, sterile manufacturing costs, supply interruptions, and reduced cefepime utilization under antimicrobial stewardship programs.

References

1. U.S. Food and Drug Administration. (n.d.). Cefepime and dextrose injection prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: The Orange Book.
3. U.S. Food and Drug Administration. (n.d.). Generic drugs and abbreviated new drug applications.